Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

被引：0
作者：
Robert M Eager
C Casey Cunningham
Neil N Senzer
Joe Stephenson
Stephen P Anthony
Steven J O'Day
Gary Frenette
Anna C Pavlick
Barry Jones
Margaret Uprichard
John Nemunaitis
机构：
[1] Mary Crowley Cancer Research Centers,Clinical Research Unit
[2] Texas Oncology PA,Department of Dermatology
[3] Baylor Sammons Cancer Center,Department of Internal Medicine
[4] Gradalis,undefined
[5] Inc,undefined
[6] Cancer Centers of the Carolinas,undefined
[7] Cancer Care Northwest,undefined
[8] The Angeles Clinic and Research Institute,undefined
[9] Carolinas Medical Center,undefined
[10] New York University Clinical Cancer Center,undefined
[11] Point Therapeutics,undefined
[12] Inc,undefined
[13] The University of Hawaii,undefined
来源：
BMC Cancer | / 9卷
关键词：
Metastatic Melanoma; Evaluable Patient; Dipeptidyl Peptidase; Fibroblast Activation Protein; Index Lesion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma
    Ghali, Helana
    Dugan, Michelle M.
    Aflatooni, Shaliz
    Boby, Aleena
    Depalo, Danielle K.
    Laborde, Jose
    Choi, Junsung
    Ahmed, Altan F.
    Zager, Jonathan S.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (13) : 9150 - 9158
  • [22] Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
    Dai, Wei Fang
    Beca, Jaclyn M.
    Croxford, Ruth
    Isaranawatchai, Wanrudee
    Menjak, Ines B.
    Petrella, Teresa M.
    Mittmann, Nicole
    Earle, Craig C.
    Gavura, Scott
    Hanna, Timothy P.
    Chan, Kelvin K. W.
    BMC CANCER, 2020, 20 (01)
  • [23] Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
    Wei Fang Dai
    Jaclyn M. Beca
    Ruth Croxford
    Wanrudee Isaranawatchai
    Ines B. Menjak
    Teresa M. Petrella
    Nicole Mittmann
    Craig C. Earle
    Scott Gavura
    Timothy P. Hanna
    Kelvin K.W. Chan
    BMC Cancer, 20
  • [24] Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
    Antoni Ribas
    Luis H Camacho
    Sun Min Lee
    Evan M Hersh
    Charles K Brown
    Jon M Richards
    Maria Jovie Rodriguez
    Victor G Prieto
    John A Glaspy
    Denise K Oseguera
    Jackie Hernandez
    Arturo Villanueva
    Bartosz Chmielowski
    Peggie Mitsky
    Nadège Bercovici
    Ernesto Wasserman
    Didier Landais
    Merrick I Ross
    Journal of Translational Medicine, 8
  • [25] Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
    Ribas, Antoni
    Camacho, Luis H.
    Lee, Sun Min
    Hersh, Evan M.
    Brown, Charles K.
    Richards, Jon M.
    Rodriguez, Maria Jovie
    Prieto, Victor G.
    Glaspy, John A.
    Oseguera, Denise K.
    Hernandez, Jackie
    Villanueva, Arturo
    Chmielowski, Bartosz
    Mitsky, Peggie
    Bercovici, Nadege
    Wasserman, Ernesto
    Landais, Didier
    Ross, Merrick I.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [26] Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate
    Vilella, R
    Benítez, D
    Milà, J
    Lozano, M
    Vilana, R
    Pomes, J
    Tomas, X
    Costa, J
    Vilalta, A
    Malvehy, J
    Puig, S
    Mellado, B
    Martí, R
    Castel, T
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (07) : 651 - 658
  • [27] Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate
    R. Vilella
    D. Benítez
    J. Milà
    M. Lozano
    R. Vilana
    J. Pomes
    X. Tomas
    J. Costa
    A. Vilalta
    J. Malvehy
    S. Puig
    B. Mellado
    R. Martí
    T. Castel
    Cancer Immunology, Immunotherapy, 2004, 53 : 651 - 658
  • [28] Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients
    Sileni, VC
    Nortilli, R
    Aversa, SML
    Paccagnella, A
    Medici, M
    Corti, L
    Favaretto, AG
    Cetto, GL
    Monfardini, S
    MELANOMA RESEARCH, 2001, 11 (02) : 189 - 196
  • [29] Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver
    Agarwala, SS
    Panikkar, R
    Kirkwood, JM
    MELANOMA RESEARCH, 2004, 14 (03) : 217 - 222
  • [30] Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma
    Sussman, Tamara A.
    Severgnini, Mariano
    Giobbie-Hurder, Anita
    Friedlander, Philip
    Swanson, Scott J.
    Jaklitsch, Michael
    Clancy, Thomas
    Goguen, Laura A.
    Lautz, David
    Swanson, Richard
    Daley, Heather
    Ritz, Jerome
    Dranoff, Glenn
    Hodi, F. Stephen
    FRONTIERS IN ONCOLOGY, 2024, 14
12345